Premium
Characteristics and prognosis for molecular breast cancer subtypes in Chinese women
Author(s) -
Zhao Jing,
Liu Hong,
Wang Meng,
Gu Lin,
Guo Xiaojing,
Gu Feng,
Fu Li
Publication year - 2009
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21307
Subject(s) - medicine , breast cancer , oncology , family history , basal (medicine) , univariate analysis , disease , menarche , multivariate analysis , population , cancer , gynecology , pathology , environmental health , insulin
Abstract Background Breast cancer is regarded as a heterogeneous disease with four molecular subtypes. However, the clinicopathological characteristics among the different subtypes have not been studied in Chinese demographic. This study clarifies the prevalence and clinicopathological features of each subtype and investigates the independent prognosis factors in the Chinese population. Methods A retrospective review of 1,820 Chinese breast cancer women were classified into different molecular subtypes based on the IHC‐based definitions for ER, PR, and HER‐2/neu to evaluate the clinicopathological features and prognosis. Results Luminal A subtype was the most prevalent with the oldest median age at first full‐term birth. The basal cell‐like subtype was associated with early onset, higher percentage of node positivity, family history of breast cancer, increased tumor size, advanced tumor grade, higher prevalence in the premenopausal group, and the earlier age at menarche. Univariate and multivariate analysis of OS and RFS identified the basal cell‐like and HER‐2/neu subtypes as negative prognostic factors. A family history was an independent predictor of shorter RFS and OS in only the basal cell‐like subtype. Conclusions The basal cell‐like subtype is associated with a poor prognosis and a family history was a negative predictor in the basal cell‐like subtype. J. Surg. Oncol. 2009;100:89–94. © 2009 Wiley‐Liss, Inc.